BioCentury | Jun 18, 2019
Company News

BeiGene, SpringWorks form MapKure to develop BRAF inhibitor

...MapKure LLC gained an exclusive license from BeiGene Ltd. (NASDAQ:BGNE; HKEX:06160) to develop and commercialize BGB-3245...
...with an initial focus on cancer. The JV is planning a Phase Ib trial of BGB-3245...
...might source other compounds. The JV’s board and a joint steering committee overseeing development of BGB-3245...
Items per page:
1 - 1 of 1